Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-center investigator-initiated study of Mavrilimumab for the treatment of patients COVID-19 infection

Next Previous
Structure search
Last 5 Searches
Advanced search AskAdis AI Search New
Trial Profile

A prospective, single-center investigator-initiated study of Mavrilimumab for the treatment of patients COVID-19 infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2020

At a glance

  • Drugs Mavrilimumab (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

Most Recent Events

  • 07 Apr 2020 New trial record
  • 31 Mar 2020 According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6).

Trial Overview

Purpose

The primary objective investigator-initiated trial will be prevention of respiratory failure in patients with COVID-19 infections.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex not stated

Trial Details

Organisations

  • Affiliations Kiniksa Pharmaceuticals

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Italy
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation Target
Mavrilimumab
Primary Drug
 		Intravenous
-
 Granulocyte macrophage colony stimulating factor, Granulocyte-macrophage colony stimulating factor receptor

Mavrilimumab

Trial History

Event Date Event Type Comment
07 Apr 2020 New trial record New trial record Updated 07 Apr 2020
31 Mar 2020 Other trial event According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6). Updated 07 Apr 2020

References

  1. Kiniksa Pharmaceuticals. Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation. Media-Rel 2020;.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Back to top